Japanese Accepted Name: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
CSV import
 
Line 26: Line 26:
{{pharmacology-stub}}
{{pharmacology-stub}}
{{No image}}
{{No image}}
__NOINDEX__

Latest revision as of 15:33, 17 March 2025

Japanese Accepted Name (JAN) is a system of nomenclature used in Japan to standardize the names of pharmaceutical substances. The system is managed by the Japanese Pharmacopoeia (JP), which is a legal document that sets the standards for the identity, quality, and purity of drugs manufactured and sold in Japan.

History[edit]

The Japanese Accepted Name system was established in 1956 by the Ministry of Health, Labour and Welfare (MHLW) in Japan. The aim was to create a standardized system of naming for pharmaceutical substances, similar to the International Nonproprietary Names (INN) system used globally.

Structure[edit]

A Japanese Accepted Name consists of a generic name, which is the non-proprietary name of the drug, and a brand name, which is the proprietary name given by the manufacturer. The generic name is usually derived from the chemical structure of the drug, while the brand name is often a trademarked name chosen by the manufacturer for marketing purposes.

Comparison with other nomenclature systems[edit]

While the JAN system is similar to the INN system, there are some differences. For example, the JAN system uses Japanese characters in addition to Latin characters, and the names are often shorter and simpler than their INN counterparts. Furthermore, the JAN system includes some drugs that are unique to Japan and not included in the INN system.

Usage[edit]

The JAN system is used in all official documents and communications related to pharmaceuticals in Japan, including the Japanese Pharmacopoeia, drug labels, and prescriptions. It is also used in scientific research and publications.

See also[edit]

References[edit]

<references />

This article is a stub related to pharmacology. You can help WikiMD by expanding it!